List of Excipients in Branded Drug KINRIX

KINRIX Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

KINRIX is GSK’s pediatric combination vaccine containing diphtheria and tetanus toxoids, acellular pertussis antigens, and inactivated poliovirus. Its excipient strategy prioritizes antigen stability, aluminum-phosphate adjuvant performance, preservative-free presentation, and compatibility with a 0.5 mL intramuscular dose. The principal commercial opportunities are in high-quality vaccine excipients, residual-control analytics, alternative adjuvant systems, prefilled delivery formats, cold-chain optimization, and differentiated combination-vaccine platforms.

KINRIX was approved by the U.S. Food and Drug Administration in 2008 for use as the fifth dose of the DTaP series and the fourth dose of the IPV series in children ages 4 through 6 years. It competes primarily with Sanofi’s Quadracel, which was approved in the United States in 2015 for the same broad booster-stage population.[1,2]

What excipients are used in KINRIX?

KINRIX uses aluminum phosphate as its adjuvant and contains residual processing substances associated with antigen manufacture. The formulation does not use an antimicrobial preservative in the final product.

Component	Functional role	Commercial relevance
Aluminum phosphate	Adjuvant that enhances and prolongs immune exposure	Large, established vaccine-adjuvant market; tight control of particle size, adsorption, and aluminum content is required
Polysorbate 80	Surfactant and stabilizer	Relevant to aggregation control, container compatibility, and oxidation management
2-Phenoxyethanol	Processing-related component associated with vaccine manufacture	Requires impurity and residual-level control
Formaldehyde	Inactivation and detoxification reagent used during manufacture	Residual-limit testing and supplier quality systems are important
Glutaraldehyde	Processing reagent associated with antigen production	Requires low-level analytical control
Neomycin, polymyxin B, and streptomycin	Antibiotics that may remain as manufacturing residues	Allergen and labeling considerations affect formulation and manufacturing strategy
Bovine serum albumin	Potential residual from cell-culture or process materials	Animal-origin control and supply-chain documentation matter
Water for injection	Vehicle	Must support suspension uniformity and sterility

The FDA prescribing information identifies the formulation and lists potential residual substances from the manufacturing process. Exact residual quantities can vary by antigen component and manufacturing lot, so commercial diligence should rely on the current product labeling, certificate of analysis, and regulatory specifications rather than a generic excipient database.[1]

Is KINRIX preservative-free?

KINRIX is supplied in a single-dose presentation and does not rely on a preservative for multidose-vial protection. That design supports pediatric acceptability and reduces exposure to preservative-related objections from parents, clinicians, and public-health purchasers.

The commercial implication is that suppliers competing for KINRIX-related business must meet vaccine-grade requirements without assuming that a conventional preservative platform has a role in the finished product. Opportunities are stronger in stabilizers, surfactants, adjuvants, container-closure systems, and analytical testing than in antimicrobial-preservative substitution.

How does the KINRIX formulation work?

KINRIX combines four DTaP antigen classes with three inactivated poliovirus serotypes. The formulation must maintain physical stability across multiple antigen components while preserving the immunological performance of aluminum phosphate.

The key formulation challenges are:

1. Maintaining consistent adsorption of antigen to aluminum phosphate.
2. Preventing sedimentation, caking, and difficult resuspension.
3. Controlling antigen degradation during refrigerated storage.
4. Avoiding excessive agitation or freeze exposure.
5. Preserving dose uniformity across the suspension.
6. Managing interactions among toxoids, pertussis proteins, surfactants, and container materials.

The product is stored under refrigerated conditions and must not be frozen. These requirements create opportunities for formulation-development companies with expertise in suspension rheology, freeze-thaw studies, container-closure compatibility, and vaccine stability modeling.

What formulation patents could protect a KINRIX-like product?

Protection for a KINRIX-like product would typically arise from several layers:

• Composition claims covering a defined antigen combination.
• Claims directed to aluminum-phosphate adsorption or antigen-to-adjuvant ratios.
• Stabilizer and surfactant combinations.
• Manufacturing processes for detoxification, purification, or inactivation.
• Methods of administering a DTaP-IPV booster to defined pediatric populations.
• Container, syringe, or dose-delivery systems.
• Quality-control methods for antigen content or residual impurities.

KINRIX is an established biologic product, and its commercial protection is unlikely to depend solely on a single formulation patent. The more relevant competitive barrier is the integrated manufacturing package: validated antigen production, potency assays, stability data, clinical comparability, and regulatory control over a multivalent product.

When did KINRIX lose regulatory exclusivity?

KINRIX received FDA approval in 2008. The product’s principal U.S. biologic exclusivity period has expired. The statutory 12-year reference-product exclusivity period under the Public Health Service Act would have ended no later than 2020, subject to the precise regulatory treatment of the product and any applicable exclusivity provisions.[1,3]

That does not mean that a competitor can immediately reproduce KINRIX. A competing vaccine must establish its own safety, immunogenicity, manufacturing controls, and regulatory compliance. Multivalent vaccines face substantial development costs because every antigen component and every combination effect must be characterized.

What is the Orange Book status of KINRIX?

KINRIX is regulated as a biologic under a Biologics License Application rather than as a conventional small-molecule drug approved under an NDA. It is therefore not typically assessed through the standard Orange Book abbreviated-new-drug-application framework used for generic tablets, capsules, and other small-molecule products.[4]

The practical consequence is that a company seeking to compete with KINRIX generally would not rely on a conventional ANDA and Paragraph IV certification. The relevant pathway is an independent biologics or vaccine application, not a standard generic substitution pathway.

Are there Paragraph IV challenges to KINRIX?

No conventional Paragraph IV challenge is expected to control KINRIX competition because Paragraph IV certifications apply to patents listed for eligible drug products in the FDA’s Orange Book. KINRIX is a biologic vaccine, and its competitive framework is based on biologics licensing, vaccine approval, and clinical comparability rather than routine small-molecule ANDA litigation.[3,4]

A company could still challenge patent rights in district court or through other patent mechanisms. Such a dispute would be separate from a traditional generic-drug Paragraph IV case.

Is KINRIX exposed to biosimilar competition?

KINRIX has low near-term biosimilar substitution risk but meaningful competition risk from independently developed combination vaccines.

A biosimilar applicant must show that its product is highly similar to a reference biologic and has no clinically meaningful differences in safety, purity, and potency. A multivalent pediatric vaccine creates technical barriers because the applicant must address several antigens, adjuvant interactions, potency assays, and manufacturing processes.[3]

The more realistic competitors are licensed combination vaccines such as Quadracel. These products compete through clinical positioning, supply reliability, government contracts, provider preference, and inclusion in immunization schedules rather than pharmacy-level automatic substitution.

Competitive factor	KINRIX	Quadracel	Commercial effect
Product class	DTaP-IPV combination vaccine	DTaP-IPV combination vaccine	Direct clinical competition
U.S. sponsor	GSK	Sanofi	Two major vaccine manufacturers
Pediatric use	Booster-stage children, generally ages 4-6	Booster-stage children, generally ages 4-6	Similar target population
Substitution model	Physician, health-system, and public-sector selection	Physician, health-system, and public-sector selection	Contracting and supply matter
Biosimilar substitution	Not the primary risk	Not the primary risk	Independent vaccine development is more relevant
Excipient differentiation	Limited because established vaccines use familiar excipient classes	Limited for the same reason	Delivery, stability, and supply advantages are more actionable

What excipient commercial opportunities exist around KINRIX?

Vaccine-grade aluminum phosphate

Aluminum phosphate is the most strategically important excipient in the formulation. Suppliers can compete through:

• Consistent particle-size distribution.
• Controlled surface chemistry.
• Reproducible antigen adsorption.
• Low endotoxin and bioburden.
• Reliable global supply.
• Regulatory documentation under pharmaceutical quality systems.

A supplier with established vaccine-adjuvant references has a stronger position than a commodity aluminum-material producer. Changing an adjuvant source in an approved vaccine can trigger comparability work, stability testing, and regulatory review.

Polysorbate 80 and oxidation control

Polysorbate 80 is widely used in biologics, but it can undergo hydrolysis and oxidation. Degradation products may affect protein stability, visible particles, and assay performance.

Commercial opportunities include:

• Low-peroxide polysorbate 80.
• Batch-to-batch impurity control.
• Improved oxidation-resistant grades.
• Packaging that limits oxygen exposure.
• Analytical methods for fatty-acid profile and degradation products.

Any excipient change must be evaluated against antigen potency, particulate formation, adsorption behavior, and container compatibility.

Residual-impurity testing

Residual formaldehyde, glutaraldehyde, antibiotics, and animal-derived materials create a specialized analytical-services market. Contract laboratories can support:

• Trace-level impurity assays.
• Lot-release testing.
• Method validation and transfer.
• Stability-indicating methods.
• Supplier qualification.
• Regulatory responses to manufacturing changes.

This opportunity is less visible than finished-dose sales but can generate recurring revenue because every commercial lot requires documented quality control.

Prefilled syringes and delivery systems

A prefilled syringe could improve administration efficiency, reduce preparation steps, and support mass-immunization workflows. The principal technical issues are suspension resuspension, syringe material compatibility, extractables and leachables, dose accuracy, and needle-shield integrity.

A delivery-system supplier would need to demonstrate that the device does not alter antigen adsorption, cause excessive particle generation, or reduce delivered dose. For a vaccine suspension, device performance is a formulation issue as well as a packaging issue.

Alternative adjuvants

Alternative aluminum salts, oil-in-water systems, and novel immunostimulatory adjuvants could improve immunogenicity or reduce antigen quantity. Their commercial potential is limited by the regulatory burden. Replacing aluminum phosphate in an established pediatric vaccine would likely require extensive nonclinical, analytical, stability, and clinical comparability work.

The opportunity is stronger for next-generation vaccines than for a direct KINRIX reformulation. An adjuvant company should position a new platform around improved immune responses, reduced dose volume, or broader protection rather than simple substitution.

What manufacturing and intellectual-property barriers affect KINRIX competition?

The main barriers are manufacturing know-how and regulatory validation.

Manufacturing barriers

KINRIX contains multiple antigen classes produced through different biological and chemical processes. A competitor must control:

• Toxoid production and detoxification.
• Purification of pertussis antigens.
• Poliovirus propagation and inactivation.
• Antigen quantification and potency.
• Aluminum adsorption.
• Aseptic filling.
• Cold-chain stability.
• Lot-release testing.

Small changes in pH, mixing energy, adsorption time, or residual reagent levels can affect product quality. These process variables may be difficult to replicate from public information.

Intellectual-property barriers

Patent risk can exist around antigen combinations, manufacturing processes, adjuvant systems, delivery devices, and analytical methods. The commercial importance of an individual patent depends on claim scope, remaining term, validity, geographic coverage, and whether a competing product uses the claimed process.

For KINRIX, the stronger barrier is likely the accumulated manufacturing and clinical package rather than a single blocking patent. A competitor should conduct a current U.S., European, Canadian, Japanese, and other major-market patent search before selecting a formulation or process.

What patent litigation and settlement risks affect KINRIX?

KINRIX is not primarily exposed to the routine patent-litigation pattern associated with high-revenue oral drugs and ANDA Paragraph IV filings. Vaccine disputes are more likely to involve:

• Process patents.
• Adjuvant or delivery patents.
• Manufacturing know-how.
• Trade-secret claims.
• Government procurement disputes.
• Product-liability or labeling issues.
• Patent challenges against a new competing vaccine.

No settlement framework comparable to a standard generic-drug launch settlement should be assumed for KINRIX. A competitor’s launch timing would depend more heavily on FDA approval, manufacturing readiness, supply contracts, and immunization-program adoption.

What is the commercial outlook for KINRIX-related excipients?

KINRIX-related excipient demand is stable but specialized. The addressable opportunity is not limited to the quantity of excipient in each 0.5 mL dose. Value is concentrated in regulatory-grade supply, quality systems, analytical testing, and change-control support.

The strongest commercial opportunities are:

1. Vaccine-grade aluminum phosphate with validated performance.
2. High-purity, low-oxidation polysorbate 80.
3. Residual-impurity testing and method validation.
4. Prefilled syringe and container-closure systems.
5. Cold-chain monitoring and stability services.
6. Alternative adjuvants for next-generation DTaP-IPV products.
7. Contract manufacturing for combination vaccines.
8. Supply-chain redundancy for government and health-system procurement.

Public sources do not provide a reliable standalone revenue figure for KINRIX. Revenue exposure should be modeled using U.S. birth cohorts, booster-dose utilization, public-sector purchasing, private immunization volume, market share relative to Quadracel, and any supply interruptions. GSK reports vaccine performance at a broader portfolio level rather than consistently disclosing KINRIX-specific sales.[5]

How does KINRIX compare with other pediatric combination vaccines?

KINRIX and Quadracel occupy the same principal booster-dose market. The differentiation is unlikely to come from a dramatic excipient difference. It is more likely to arise from:

• Procurement price.
• Product availability.
• Contract terms.
• Provider familiarity.
• Packaging and administration efficiency.
• Regulatory history.
• Manufacturing reliability.
• Public-health purchasing decisions.

For an excipient or device supplier, winning business from an established vaccine manufacturer requires more than a lower unit price. The supplier must show equivalent or superior quality, a defensible change-control package, reliable capacity, and minimal impact on regulatory filings.

Key Takeaways

• KINRIX is a DTaP-IPV combination vaccine approved for the booster-stage pediatric population.
• Aluminum phosphate is the central adjuvant and the most commercially important formulation component.
• Polysorbate 80 supports formulation stability but creates oxidation and compatibility-control requirements.
• Formaldehyde, glutaraldehyde, antibiotics, and bovine serum albumin may occur as manufacturing residuals and require analytical control.
• KINRIX is a biologic vaccine, so conventional Orange Book generic substitution and Paragraph IV litigation are not the principal competition model.
• Biosimilar risk is lower than independent competition from other licensed combination vaccines, particularly Quadracel.
• The strongest excipient opportunities are in validated aluminum phosphate, high-purity polysorbate 80, residual testing, delivery systems, and cold-chain services.
• Reformulation of an approved vaccine faces substantial comparability and regulatory barriers.
• KINRIX-specific revenue is not consistently disclosed publicly, so commercial exposure must be estimated from dose volume, market share, procurement, and supply data.
• Manufacturing know-how, validated assays, and regulatory history may be more important barriers than a single blocking patent.

FAQs

Can aluminum phosphate in KINRIX be replaced with aluminum hydroxide?

Potentially, but the change would require extensive comparability testing. The two adjuvants differ in surface charge, adsorption behavior, sedimentation, and interaction with antigen proteins. A direct substitution would not be a simple excipient change.

Does KINRIX contain thimerosal?

The single-dose KINRIX presentation is not formulated with thimerosal as a preservative. The current FDA-approved labeling should control for presentation-specific composition and residual-substance information.[1]

Could a low-oxidation polysorbate 80 improve KINRIX stability?

It could reduce one source of formulation variability, but the benefit would need to be demonstrated through degradation, particulate, potency, adsorption, and stability studies. It would not automatically justify a commercial formulation change.

Is Quadracel a generic version of KINRIX?

No. Quadracel is a separately licensed DTaP-IPV vaccine from Sanofi. It competes clinically with KINRIX but is not an FDA-approved generic or biosimilar copy of KINRIX.[2]

What is the best entry point for an excipient company targeting KINRIX?

The most credible entry points are qualified aluminum phosphate, specialty polysorbate 80, residual-impurity analytics, container-closure systems, and stability services. Direct substitution in the approved commercial formulation is more difficult than supplying a new vaccine program or supporting a manufacturing expansion.

References

1. U.S. Food and Drug Administration. (2024). KINRIX [package insert]. GlaxoSmithKline Biologicals.

2. U.S. Food and Drug Administration. (2015). Quadracel approval letter and prescribing information. Sanofi Pasteur.

3. U.S. Food and Drug Administration. (2023). Biosimilar and interchangeable products. https://www.fda.gov/drugs/biosimilars

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugsatfda

5. GSK plc. (2024). Annual report 2023. https://www.gsk.com/en-gb/investors/financial-results/annual-report/